SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 102.05+0.3%Nov 21 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Tauscher who wrote (921)3/22/1999 1:00:00 AM
From: RCMac  Read Replies (1) of 3202
 
Steve,
The AFFX v. INCY suit is about more than the patent issue, I understand from Murphy's newsletter, which I paraphrased on the point in an earlier post:

Message 7735800

This sounds to me more like some sort of claim of theft of trade secrets. Such a claim could be based on essentially the same basic facts - use by INCY/Synteni of a process owned by AFFX - as a patent claim, but would not depend on the validity of any patent. Instead, AFFX would probably need to prove that such a theft took place, and that INCY was using the stolen intellectual property. If I am reading Murphy's fragmentary report correctly, the injunction (at least as based on this part of the lawsuit) would be against INCY's continued use of the "stolen" IP, which Murphy says is worth about 6% of INCY's business.

I don't know how much this helps. I will try to phone INCY's in-house lawyers sometime this week, to see if I can learn more about the lawsuit.

-- RCM
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News